CD274 and cancer: As the application of anti-PD-1/PD-L1 therapy across various solid tumors has increased in recent years, detailed criteria for evaluating PD-L1 expression through immunohistochemistry have been established for specific cancers, making PD-L1 the most validated and used immune checkpoint.